ImprimisRx announced its FDA-registered 503B outsourcing facility received a non-resident operating license and is now shipping to California. The license allows California-based ophthalmologists, optometrists, surgery centers, and hospitals to order and stock more than 40 ImprimisRx ophthalmic products for on-demand administration.
“Our team is excited to begin serving our home state of California, and its nearly 40 million residents, with high-quality ophthalmic formulations from our FDA-registered 503B outsourcing facility. We are grateful the State of California has issued this permit, one that has been granted to only a select few of the outsourcing facilities registered with the FDA,” said John Saharek, President of ImprimisRx.
ImprimisRx currently serves thousands of ophthalmologists and optometrists in all 50 states, and has 40 proprietary ophthalmic formulations, including treatments for myopia, glaucoma, postoperative eye pain, and more. These treatments are made available to patients at affordable prices through partnering with healthcare providers and pharmacy benefit managers.
You can read more here.